MedTrace Logo

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

NCT06326086 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2024-03-22

No results posted yet for this study

Summary

Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.

Conditions

Interventions

DRUG

Chemotherapy drug

Chemotherapy drug as prescribed by primary treating physician

DRUG

Targeted Agent

Targeted agents as prescribed by primary treating physician

DRUG

Immunotherapy

Immunotherapy as prescribed by primary treating physician

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-08-01
Completion
2024-08-01

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326086 on ClinicalTrials.gov